Paul Zeun

List of Publications by Citations

156 papers	7,302 citations	37 h-index	83 g-index
173 ext. papers	9,130 ext. citations	8 avg, IF	5.98 L-index

#	Paper	IF	Citations
156	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. *Lancet Neurology, The*, **2009**, 8, 791-801	24.1	721
155	Huntington disease. *Nature Reviews Disease Primers*, **2015**, 1, 15005	51.1	672
154	Huntington disease: natural history, biomarkers and prospects for therapeutics. *Nature Reviews Neurology*, **2014**, 10, 204-16	15	600
153	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *Lancet Neurology, The*, **2013**, 12, 637-49	24.1	557
152	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. *Lancet Neurology, The*, **2011**, 10, 31-42	24.1	443
151	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. *Lancet Neurology, The*, **2012**, 11, 42-53	24.1	392
150	Targeting Huntingtin Expression in Patients with Huntington's Disease. *New England Journal of Medicine*, **2019**, 380, 2307-2316	59.2	319
149	Therapies targeting DNA and RNA in Huntington's disease. *Lancet Neurology, The*, **2017**, 16, 837-847	24.1	175
148	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. *Lancet Neurology, The*, **2017**, 16, 601-609	24.1	172
147	Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. *Human Molecular Genetics*, **2000**, 9, 2683-9	5.6	166
146	Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. *Movement Disorders*, **2016**, 31, 436-57	7	148
145	DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. *Annals of Neurology*, **2016**, 79, 983-90	9.4	135
144	Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease. *Neuron*, **2019**, 101, 801-819	13.9	102
143	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. *EBioMedicine*, **2015**, 2, 1420-9	8.8	91
142	The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients. *Scientific Reports*, **2017**, 7, 1307	4.9	89
141	Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. *Neurobiology of Disease*, **2015**, 83, 115-21	7.5	87
140	Emotion recognition in Huntington's disease: a systematic review. *Neuroscience and Biobehavioral Reviews*, **2012**, 36, 237-53	9	75

139	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. *Brain*, **2015**, 138, 3016-29	11.2	71
138	A SNP in the HTT promoter alters NF-B binding and is a bidirectional genetic modifier of Huntington disease. *Nature Neuroscience*, **2015**, 18, 807-16	25.5	70
137	KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E4676-E4685	11.5	65
136	Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. *PLOS Currents*, **2010**, 2,		64
135	A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. *EBioMedicine*, **2019**, 48, 568-580	8.8	63
134	Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. *Neurology*, **2017**, 89, 2495-2502	6.5	57
133	DNA repair in the trinucleotide repeat disorders. *Lancet Neurology, The*, **2017**, 16, 88-96	24.1	56
132	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. *Lancet Neurology, The*, **2020**, 19, 502-512	24.1	56
131	FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat. *Human Molecular Genetics*, **2019**, 28, 650-661	5.6	56
130	Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes. *Biological Psychiatry*, **2018**, 83, 456-465	7.9	54
129	Clinical Features of Huntington's Disease. *Advances in Experimental Medicine and Biology*, **2018**, 1049, 1-28	3.6	53
128	White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression. *Cortex*, **2014**, 52, 98-112	3.8	46
127	Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system. *Acta Neuropathologica*, **2016**, 131, 411-25	14.3	44
126	The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. *Neuropsychologia*, **2015**, 79, 138-46	3.2	42
125	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. *Neurology*, **2018**, 90, e717-e723	6.5	42
124	Antisense oligonucleotides for neurodegeneration. *Science*, **2020**, 367, 1428-1429	33.3	41
123	Operationalizing compensation over time in neurodegenerative disease. *Brain*, **2017**, 140, 1158-1165	11.2	39
122	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. *Journal of Neurochemistry*, **2016**, 139, 22-5	6	37

121	Huntington disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2018**, 147, 255-278	3	37
120	Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. *Neurobiology of Disease*, **2015**, 73, 388-98	7.5	37
119	Incidence of adult Huntington's disease in the UK: a UK-based primary care study and a systematic review. *BMJ Open*, **2016**, 6, e009070	3	36
118	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease. *PLoS ONE*, **2016**, 11, e0163479	3.7	35
117	Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease. *Journal of the International Neuropsychological Society*, **2016**, 22, 595-608	3.1	33
116	RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. *Human Molecular Genetics*, **2016**, 25, 2893-2904	5.6	33
115	Task-specific training in Huntington disease: a randomized controlled feasibility trial. *Physical Therapy*, **2014**, 94, 1555-68	3.3	32
114	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. *Journal of the Neurological Sciences*, **2016**, 368, 243-8	3.2	32
113	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. *Movement Disorders Clinical Practice*, **2019**, 6, 541-546	2.2	30
112	Gene suppression approaches to neurodegeneration. *Alzheimer's Research and Therapy*, **2017**, 9, 82	9	30
111	In vivo characterization of white matter pathology in premanifest huntington's disease. *Annals of Neurology*, **2018**, 84, 497-504	9.4	29
110	Correction of inter-scanner and within-subject variance in structural MRI based automated diagnosing. *NeuroImage*, **2014**, 98, 405-15	7.9	29
109	Prion degradation pathways: Potential for therapeutic intervention. *Molecular and Cellular Neurosciences*, **2015**, 66, 12-20	4.8	29
108	Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners. *Journal of Huntington's Disease*, **2013**, 2, 159-75	1.9	29
107	Validation of a prognostic index for Huntington's disease. *Movement Disorders*, **2017**, 32, 256-263	7	27
106	Neuropsychiatry and White Matter Microstructure in Huntington's Disease. *Journal of Huntington's Disease*, **2015**, 4, 239-49	1.9	27
105	A Computational Cognitive Biomarker for Early-Stage Huntington's Disease. *PLoS ONE*, **2016**, 11, e0148409	3.7	27
104	Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis. *Current Opinion in Pharmacology*, **2016**, 26, 33-8	5.1	26

103	Interregional compensatory mechanisms of motor functioning in progressing preclinical neurodegeneration. *NeuroImage*, **2013**, 75, 146-154	7.9	26
102	Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. *Journal of Neurochemistry*, **2016**, 137, 782-94	6	26
101	Stimulating neural plasticity with real-time fMRI neurofeedback in Huntington's disease: A proof of concept study. *Human Brain Mapping*, **2018**, 39, 1339-1353	5.9	24
100	Longitudinal Diffusion Tensor Imaging Shows Progressive Changes in White Matter in Huntington's Disease. *Journal of Huntington's Disease*, **2015**, 4, 333-46	1.9	24
99	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. *Science Translational Medicine*, **2020**, 12,	17.5	24
98	The Dementias Platform UK (DPUK) Data Portal. *European Journal of Epidemiology*, **2020**, 35, 601-611	12.1	23
97	Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease. *Frontiers in Neurology*, **2017**, 8, 519	4.1	23
96	Overlap between age-at-onset and disease-progression determinants in Huntington disease. *Neurology*, **2018**, 90, e2099-e2106	6.5	22
95	Association of CAG Repeats With Long-term Progression in Huntington Disease. *JAMA Neurology*, **2019**, 76, 1375-1385	17.2	22
94	Corpus callosal atrophy in premanifest and early Huntington's disease. *Journal of Huntington's Disease*, **2013**, 2, 517-26	1.9	21
93	The human motor cortex microcircuit: insights for neurodegenerative disease. *Nature Reviews Neuroscience*, **2020**, 21, 401-415	13.5	20
92	George Huntington: a legacy of inquiry, empathy and hope. *Brain*, **2016**, 139, 2326-33	11.2	20
91	A critical evaluation of inflammatory markers in Huntington's Disease plasma. *Journal of Huntington's Disease*, **2013**, 2, 125-34	1.9	19
90	Testing a longitudinal compensation model in premanifest Huntington's disease. *Brain*, **2018**, 141, 2156-2166	11.6	19
89	Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells. *Scientific Reports*, **2017**, 7, 46740	4.9	18
88	Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. *Human Brain Mapping*, **2017**, 38, 2819-2829	5.9	17
87	Short-interval observational data to inform clinical trial design in Huntington's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 1291-8	5.5	17
86	Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly. *Drugs and Aging*, **2018**, 35, 959-971	4.7	17

85	Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington'S Disease Model. *Brain Communications*, **2020**, 2, fcaa066	4.5	16
84	Biomarker development for Huntington's disease. *Drug Discovery Today*, **2014**, 19, 972-9	8.8	16
83	Predicting clinical diagnosis in Huntington's disease: An imaging polymarker. *Annals of Neurology*, **2018**, 83, 532-543	9.4	15
82	Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease. *Human Brain Mapping*, **2016**, 37, 4615-4628	5.9	15
81	Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease. *Annals of Neurology*, **2020**, 87, 751-762	9.4	14
80	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. *NeuroImage: Clinical*, **2018**, 17, 312-324	5.3	14
79	Structural imaging in premanifest and manifest Huntington disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2017**, 144, 247-261	3	14
78	Inconsistent emotion recognition deficits across stimulus modalities in Huntington?s disease. *Neuropsychologia*, **2014**, 64, 99-104	3.2	13
77	Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance. *Human Brain Mapping*, **2016**, 37, 67-80	5.9	13
76	Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction. *FASEB Journal*, **2020**, 34, 8139-8154	0.9	12
75	Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice. *Scientific Reports*, **2017**, 7, 14275	4.9	11
74	Natural biological variation of white matter microstructure is accentuated in Huntington's disease. *Human Brain Mapping*, **2018**, 39, 3516-3527	5.9	11
73	Skeletal muscle atrophy in R6/2 mice - altered circulating skeletal muscle markers and gene expression profile changes. *Journal of Huntington's Disease*, **2014**, 3, 13-24	1.9	11
72	Therapeutic Antisense Targeting of Huntingtin. *DNA and Cell Biology*, **2020**, 39, 154-158	3.6	11
71	Expanding the Spectrum of Movement Disorders Associated With Hexanucleotide Expansions. *Neurology: Genetics*, **2021**, 7, e575	3.8	11
70	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. *JAMA Neurology*, **2017**, 74, 1352-1360	17.2	10
69	Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease. *Journal of Huntington's Disease*, **2012**, 1, 97-106	1.9	10
68	Dynamics of Cortical Degeneration Over a Decade in Huntington's Disease. *Biological Psychiatry*, **2021**, 89, 807-816	7.9	10

67	Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study. *NeuroImage: Clinical*, **2018**, 19, 66-70	5.3	9
66	In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease. *Scientific Reports*, **2018**, 8, 11447	4.9	9
65	Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays. *PLoS ONE*, **2017**, 12, e0189891	3.7	9
64	Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?. *Movement Disorders*, **2019**, 34, 584-585	7	8
63	The potential of composite cognitive scores for tracking progression in Huntington's disease. *Journal of Huntington's Disease*, **2014**, 3, 197-207	1.9	8
62	Design optimization for clinical trials in early-stage manifest Huntington's disease. *Movement Disorders*, **2017**, 32, 1610-1619	7	8
61	Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntington's Disease. *Journal of Huntington's Disease*, **2015**, 4, 371-82	1.9	8
60	Reference genes selection for transcriptional profiling in blood of HD patients and R6/2 mice. *Journal of Huntington's Disease*, **2013**, 2, 185-200	1.9	8
59	Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease. *Neuropsychology*, **2018**, 32, 958-965	3.8	8
58	Altered Intracortical T-Weighted/T-Weighted Ratio Signal in Huntington's Disease. *Frontiers in Neuroscience*, **2018**, 12, 805	5.1	8
57	FAN1 controls mismatch repair complex assembly via MLH1 retention to stabilize CAG repeat expansion in Huntington's disease. *Cell Reports*, **2021**, 36, 109649	10.6	8
56	Age of onset in Huntington's disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes. *Brain*, **2017**, 140, e42	11.2	7
55	Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment. *Scientific Reports*, **2019**, 9, 7202	4.9	7
54	Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials. *Parkinsonism and Related Disorders*, **2019**, 63, 179-184	3.6	7
53	Disease Onset in Huntington's Disease: When Is the Conversion?. *Movement Disorders Clinical Practice*, **2021**, 8, 352-360	2.2	7
52	One decade ago, one decade ahead in huntington's disease. *Movement Disorders*, **2019**, 34, 1434-1439	7	6
51	Test-Retest Reliability of Measures Commonly Used to Measure Striatal Dysfunction across Multiple Testing Sessions: A Longitudinal Study. *Frontiers in Psychology*, **2017**, 8, 2363	3.4	6
50	Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes. *PLoS ONE*, **2015**, 10, e0141793	3.7	6

49	Characterizing White Matter in Huntington's Disease. *Movement Disorders Clinical Practice*, **2020**, 7, 52-60	2.2	6
48	Composite UHDRS Correlates With Progression of Imaging Biomarkers in Huntington's Disease. *Movement Disorders*, **2021**, 36, 1259-1264	7	6
47	Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling. *Frontiers in Human Neuroscience*, **2015**, 9, 634	3.3	5
46	Diffusion imaging in Huntington's disease: comprehensive review. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**,	5.5	5
45	Relating quantitative 7T MRI across cortical depths to cytoarchitectonics, gene expression and connectomics. *Human Brain Mapping*, **2021**, 42, 4996-5009	5.9	5
44	Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. *PLOS Currents*, **2016**, 8,		4
43	A MDS Evidence-Based Review on Treatments for Huntington's Disease. *Movement Disorders*, **2021**,	7	4
42	Wild-type huntingtin regulates human macrophage function. *Scientific Reports*, **2020**, 10, 17269	4.9	4
41	Activity or connectivity? A randomized controlled feasibility study evaluating neurofeedback training in Huntington's disease. *Brain Communications*, **2020**, 2, fcaa049	4.5	4
40	Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study. *EBioMedicine*, **2021**, 65, 103266	8.8	4
39	Human Huntington's disease pluripotent stem cell-derived microglia develop normally but are abnormally hyper-reactive and release elevated levels of reactive oxygen species. *Journal of Neuroinflammation*, **2021**, 18, 94	10.1	4
38	Genetic testing in dementia - utility and clinical strategies. *Nature Reviews Neurology*, **2021**, 17, 23-36	15	4
37	Working Memory-Related Effective Connectivity in Huntington's Disease Patients. *Frontiers in Neurology*, **2018**, 9, 370	4.1	4
36	Longitudinal expression changes are weak correlates of disease progression in Huntington's disease. *Brain Communications*, **2020**, 2, fcaa172	4.5	3
35	Fronto-striatal circuits for cognitive flexibility in far from onset Huntington's disease: evidence from the Young Adult Study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 143-149	5.5	3
34	Longitudinal Structural MRI in Neurologically Healthy Adults. *Journal of Magnetic Resonance Imaging*, **2020**, 52, 1385-1399	5.6	2
33	Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease. *Neurology: Genetics*, **2021**, 7, e617	3.8	2
32	Imbalanced basal ganglia connectivity is associated with motor deficits and apathy in Huntington's disease. *Brain*, **2021**,	11.2	2

31	A new family with GLRB-related hyperekplexia showing chorea in homo- and heterozygous variant carriers. *Parkinsonism and Related Disorders*, **2020**, 79, 97-99	3.6	2
30	Apathy Associated With Impaired Recognition of Happy Facial Expressions in Huntington's Disease. *Journal of the International Neuropsychological Society*, **2019**, 25, 453-461	3.1	2
29	Polyglutamine diseases. *Current Opinion in Neurobiology*, **2021**, 72, 39-47	7.6	2
28	A small molecule kicks repeat expansion into reverse. *Nature Genetics*, **2020**, 52, 136-137	36.3	1
27	Reply letter to Jinnah "Locus pocus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification": Necessary evolution, no magic!. *Movement Disorders*, **2016**, 31, 1760-1762	7	1
26	Timing of selective basal ganglia white matter loss in premanifest Huntington's disease.. *NeuroImage: Clinical*, **2022**, 33, 102927	5.3	1
25	Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington's Disease. *Frontiers in Neurology*, **2021**, 12, 616272	4.1	1
24	Reply to 'Topographical layer imaging as a tool to track neurodegenerative disease spread in M1'. *Nature Reviews Neuroscience*, **2021**, 22, 69	13.5	1
23	Timing of selective basal ganglia white matter loss in Huntington disease		1
22	A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntington's Disease. *Frontiers in Big Data*, **2021**, 4, 662200	2.8	1
21	Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, **2021**, 6, 910-918	3.4	1
20	Huntington Disease Integrated Staging System (HD-ISS): A Novel Evidence-Based Classification System For Staging		1
19	Mislocalization of Nucleocytoplasmic Transport Proteins in Human Huntington's Disease PSC-Derived Striatal Neurons. *Frontiers in Cellular Neuroscience*, **2021**, 15, 742763	6.1	1
18	Altered nuclear architecture in blood cells from Huntington's disease patients. *Neurological Sciences*, **2021**, 1	3.5	0
17	Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers. *Movement Disorders*, **2021**, 36, 2282-2292	7	0
16	CAG Somatic Instability in a Huntington Disease Expansion Carrier Presenting with a Progressive Supranuclear Palsy-like Phenotype.. *Movement Disorders*, **2022**,	7	0
15	Multimodal characterization of the visual network in Huntington's disease gene carriers. *Clinical Neurophysiology*, **2019**, 130, 2053-2059	4.3	
14	D20 Operationalising compensation over time in neurodegenerative disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A41.2-A41	5.5	

13	D4 Prediction of huntington disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A35.1-A35	5.5
12	D8 Tms-eeg markers of inhibitory deficits in huntington disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A36.2-A36	5.5
11	D22 Compensation in preclinical huntington disease: evidence from the track-on HD study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A42.2-A42	5.5
10	Response to the letter to the editor by Reilmann et al referring to our article titled "Motor cortex synchronization influences the rhythm of motor performance in premanifest Huntington's disease". *Movement Disorders*, **2018**, 33, 1371	7
9	The application of NMR-based metabonomics in neurological disorders. *Neurotherapeutics*, **2006**, 3, 358-372	3.4
8	Opportunity cost determines free-operant action initiation latency and predicts apathy. *Psychological Medicine*,1-10	6.9
7	9 Aberrant striatal value representation in Huntington disease gene carriers 25 years before onset. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, e4.1-e4	5.5
6	D16 White matter microstructure and natural biological variation in huntington disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A39.2-A39	5.5
5	K4 The cost and value of a huntington disease multidisciplinary team meeting. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A80.2-A80	5.5
4	D21 Longitudinal compensation in the cognitive network in huntington disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A42.1-A42	5.5
3	B48 DNA repair pathways as a common genetic mechanism modulating the age at onset in polyglutamine diseases. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A26.1-A26	5.5
2	Learning Subject-Specific Directed Acyclic Graphs With Mixed Effects Structural Equation Models From Observational Data. *Frontiers in Genetics*, **2018**, 9, 430	4.5
1	Suppression of Somatic Expansion As a Novel Therapeutic Approach for Huntington Disease and Other Repeat Expansion Disorders **2022**, 1, 163-175	